Highlights of This Issue 5145

SPECIAL FEATURES

CCR Translations

5147  Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein
See related article, p. 5290

CCR New Strategies

5150  New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
Joyce Liu and Ursula A. Matulonis

Molecular Pathways

5157  Molecular Pathways: Myeloid Complicity in Cancer
Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

CCR Focus

5172  The Lymphoma Medicine Cabinet
Susan E. Bates

5173  Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context
Owen A. O’Connor and Kensei Tobinai

5182  Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype
Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

5194  New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klappler on behalf of the European Mantle Cell Lymphoma Network

5207  Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas
Emanuele Zucca, Francesco Bertoni, Barbara Vannata, and Franco Cavalli

5217  Human T-cell Lymphotropic Virus Type I-Associated Adult T-cell Leukemia-Lymphoma: New Directions in Clinical Research
Kunihiro Tsukasaki and Kensei Tobinai

5226  Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?
Emmanuel Bachy and Gilles Salles

5240  Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice
Owen A. O’Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D’Amore, Dejan Radeski, and Susan E. Bates

CANCER THERAPY: CLINICAL

5255  A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodríguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

PERSONALIZED MEDICINE AND IMAGING

5265  Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5272</td>
<td>Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort</td>
<td>Trine Tramm, Hayat Mohammed, Simen Myhr, Marianne Kyndt, Jan Alsner, Anne-Lise Borresen-Dale, Therese Sørlie, Arnoldo Frigessi, and Jens Overgaard</td>
<td></td>
</tr>
<tr>
<td>5281</td>
<td>Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer</td>
<td>Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve A. Lowery, Leonard B. Saltz, Joseph F. Crotty, Kristen Gary, Brandon Cooper, Rena Lapidus, Mariola Sadowska, and Eileen M. O’Reilly</td>
<td></td>
</tr>
<tr>
<td>5290</td>
<td>Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors</td>
<td>Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak</td>
<td></td>
</tr>
<tr>
<td>5302</td>
<td>Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics</td>
<td>Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni</td>
<td></td>
</tr>
<tr>
<td>5311</td>
<td>Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer</td>
<td>Stefan Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakshit, Aidan Noon, Wei Chen, and James WF Catto</td>
<td></td>
</tr>
<tr>
<td>5331</td>
<td>Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study</td>
<td>Tammy Ho, Lauren E. Howard, Adriana C. Vidal, Leah Gerber, Daniel Moreira, Madeleine McKeever, Gerald Andriole, Ramiro Castro-Santamaria, and Stephen J. Freedland</td>
<td></td>
</tr>
<tr>
<td>5339</td>
<td>Correction: Targeting miR21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.